Systematic review of the effectiveness of pharmacologic interventions to improve quality of life and well-being in people with dementia

American Journal of Geriatric Psychiatry

Volumn 21, Issue 2, 2013, Pages 173-183

  Cooper, Claudia ^a   Mukadam, Naaheed ^a   Katona, Cornelius ^a   Lyketsos, Constantine G ^b   Blazer, Dan ^f   Ames, David ^c,d   Rabins, Peter ^b   Brodaty, Henry ^c,d   De Mendonça Lima, Carlos ^e   Livingston, Gill ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e Centro Hospitalar Do Alto Ave ^*  (Portugal)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dementia; Quality of life; Systematic review

Indexed keywords

DONEPEZIL; GINKGO BILOBA EXTRACT; MEMANTINE; NAPROXEN; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ROFECOXIB; SERTRALINE; TARENFLURBIL; TESTOSTERONE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL EFFECTIVENESS; COGNITION; DEMENTIA; DEPRESSION; DIET SUPPLEMENTATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; FOLLOW UP; HAPPINESS; HUMAN; LIFE SATISFACTION; MENTAL DISEASE; META ANALYSIS; OUTCOME ASSESSMENT; PLEASURE; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 85027931444     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1016/j.jagp.2012.10.018     Document Type: Article

References (33)

1. Ferri CP, Prince M, Brayne C, et al: Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366(9503):2112-2117
2. Christensen K, Doblhammer G, Rau R, Vaupel JW: Ageing populations: the challenges ahead. Lancet 2009; 374(9696):1196-1208
3. Hoe J, Katona C, Orrell M, Livingston G: Quality of life in dementia: care recipient and caregiver perceptions of quality of life in dementia: the LASER-AD study. Int J Geriatr Psychiatry 2007; 22(10):1031-1036
4. World Health Organization: Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med 1995; 41(10):1403-1409
5. Albert SM, Del Castillo-Castaneda C, Sano M, et al: Quality of life in patients with Alzheimer's disease as reported by patient proxies. J Am Geriatr Soc 1996; 44(11):1342-1347
6. Logsdon R, Gibbons LE, McCurry SM: Quality of life in Alzheimer's disease: patient and caregiver reports. J Ment Health Aging 1996; 5:21-32
7. Birks JS, Harvey RJ: Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2003; (3); CD001190
8. Birks J, Grimley Evans J: Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2007; (2); CD003120
9. Weinmann S, Roll S, Schwarzbach C, et al: Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr 2011; 17(10):14
10. Cooper C, Katona C, Lyketsos C, et al: A systematic review of treatments for refractory depression in older people. Am J Psychiatry 2011; 168(7):681-688
11. Livingston G, Johnston K, Katona C, et al: Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry 2005; 162(11): 1996-2021
12. Selwood A, Johnston K, Katona C, et al: Systematic review of the effect of psychological interventions on family caregivers of people with dementia. J Affect Disord 2007; 101(1-3): 75-89
13. StatsDirect [computer program]. Version 2.6.6. Cheshire, United Kingdom, StatsDirect Ltd, 2008
14. Egger M, Smith GD, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629-634
15. Weintraub D, Rosenberg PB, Drye LT, et al: Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry 2010; 18(4):332-340
16. Ballard CG, Thomas A, Fossey J, et al: A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry 2004; 65(1):114-119
17. Bakchine S, Loft H: Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double blind, placebo-controlled 6-month study. J Alzheimers Dis 2008; 13(1):97-107
18. Burns A, Rossor M, Hecker J, et al: The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10(3):237-244
19. Rogers SL, Friedhoff LT: The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 1996; 7(6):293-303
20. Rogers SL, Farlow MR, Doody RS, et al: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50(1):136-145
21. Rogers SL, Doody RS, Mohs RC, et al: Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158(9):1021-1031
22. Fontaine CS, Hynan LS, Koch K, et al: A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry 2003; 64(6):726-730
23. Ihl R, Bachinskaya N, Korczyn AD, et al: Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. Int J Geriatr Psychiatry [published online ahead of print December 21, 2010] doi:10.1002/gps.2662
24. Scheltens P, Kamphuis PJ, Verhey FR, et al: Efficacy of a medical food in mild Alzheimer's disease: a randomized, controlled trial. Alzheimers Dement 2010; 6(1):1-10
25. Green RC, Schneider LS, Amato DA, et al: Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009; 302(23):2557-2564
26. Lu PH, Masterman DA, Mulnard R, et al: Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol 2006; 63(2): 177-185
27. McCarney R, Fisher P, Iliffe S, et al: Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial. Int J Geriatr Psychiatry 2008; 23(12):1222-1230
28. Aisen PS, Schafer KA, Grundman M, et al: Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289(21): 2819-2826
29. Sultzer DL, Davis SM, Tariot PN, et al: Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 2008; 165(7):844-854
30. Livingston G, Cooper C, Woods J, et al: Successful ageing in adversity: the LASER-AD longitudinal study. J Neurol Neurosurg Psychiatry 2008; 79(6):641-645
31. Cordner Z, Blass DM, Rabins PV, et al: Quality of life in nursing home residents with advanced dementia. J Am Geriatr Soc 2010; 58(12):2394-2400
32. Hoe J, Hancock G, Livingston G, et al: Quality of life of people with dementia in residential care homes. Br J Psychiatry 2006; 188(5):460-464
33. Cooper C, Mukadam N, Katona C, et al: Systematic review of the effectiveness of non-pharmacological interventions to improve quality of life in people with dementia. Int Psychogeriatr 2012; 24:856-870